REG - ValiRx PLC - Exercise of Warrant

ValiRxAnnouncement

29/09/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20200929:nRSc3581Aa

RNS Number : 3581A  ValiRx PLC  29 September 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Exercise of Warrant

 

London, UK 29 September 2020: ValiRx Plc (AIM: VAL), the clinical stage
biotechnology company announces it has received notification for the exercise
of warrants over 60,000 ordinary shares in the Company at an exercise price of
25 pence per share providing the Company with proceeds of £15,000 ("Warrant
Exercise").

 

Application will be made to the London Stock Exchange to admit the 60,000 new
ordinary shares resulting from the Warrant Exercise to trading on AIM.
Admission of the new ordinary shares is expected to occur on or around 2
October 2020.  The new ordinary shares will rank pari passu with the existing
ordinary shares.

 

For the purposes of the Disclosure and Transparency Rules, following the issue
of shares detailed above as a result of the Warrant Exercise, the enlarged
issued share capital of the Company will comprise 58,849,423 ordinary shares
of 0.1 pence each. The Company does not hold any shares in treasury. The above
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company, under the Disclosure and
Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

 

For further information please contact:

 

 ValiRx plc                                         Tel: +44 (0) 20 7073 2628

                           www.valirx.com (http://www.valirx.com/)
 Suzanne Dilly                                      Suzanne.Dilly@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)   Tel: +44 (0) 20 7213 0880

 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Sole Broker)           Tel: +44 (0) 20 7469 0930

 Duncan Vasey / Lucy Williams / Eran Zucker

 Optimum Strategic Communications                   Tel: +44 (0) 20 8148 3040

 Supriya Mathur/ Shabnam Bashir                     valirx@optimumcomms.com (mailto:valirx@optimumcomms.com)

 

 About ValiRx

 ValiRx accelerates the development of treatments in oncology and women's
 health to improve patient lives. We provide the scientific, financial and
 commercial framework to enable rapid translation of innovative science into
 clinical development.

 With our extensive and proven experience in research and drug development, we
 select and incubate promising novel drug candidates and guide them through an
 optimised process of development, from pre-clinical studies to clinic and
 investor-ready assets.

 Integrating science and business

 We connect diverse disciplines across scientific, technical and commercial
 domains, with the promise of achieving a more streamlined, less costly, drug
 development process.  We work closely with our selected collaborators and
 leverage the combined expertise required for science to advance.

 Lead candidates from our portfolio are out-licenced or partnered with
 investors through ValiRx subsidiary companies for further clinical development
 and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

 

 

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's
health to improve patient lives. We provide the scientific, financial and
commercial framework to enable rapid translation of innovative science into
clinical development.

 

With our extensive and proven experience in research and drug development, we
select and incubate promising novel drug candidates and guide them through an
optimised process of development, from pre-clinical studies to clinic and
investor-ready assets.

 

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial
domains, with the promise of achieving a more streamlined, less costly, drug
development process.  We work closely with our selected collaborators and
leverage the combined expertise required for science to advance.

 

Lead candidates from our portfolio are out-licenced or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation. https://www.valirx.com/ (https://www.valirx.com/)

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSEAKNPASXEEFA